October 16, 2024
October 12, 2024
October 12, 2024
In August 2024, CureLab Oncology's CEO, Dr. Alexander Shneider, presented at the Immuno-Oncology Summit 2024. His presentation focused on the company's novel plasmid-based therapy, Elenagen, which initially aimed to be an anti-cancer DNA vaccine but serendipitously revealed broader therapeutic applications.
CureLab Oncology's Elenagen: DNA Vaccine Shows Promise in Immuno-Oncology and Beyond
In August 2024, CureLab Oncology's CEO, Dr. Alexander Shneider, presented at the Immuno-Oncology Summit 2024. His presentation focused on the company's novel plasmid-based therapy, Elenagen, which initially aimed to be an anti-cancer DNA vaccine but serendipitously revealed broader therapeutic applications. September 23, 2024
September 23, 2024
Clinical-stage pre-IPO biotech company is leveraging translational science to extend the healthy lives of beloved companions; this offering is limited to accredited investors.
CureLab Veterinary Announces $15 Million Regulation D Offering to Advance Cancer and Inflammatory Disease Treatments for Pets
Clinical-stage pre-IPO biotech company is leveraging translational science to extend the healthy lives of beloved companions; this offering is limited to accredited investors.August 8, 2024
